Journal of Clinical Oncology
Articles in this Issue
Non-invasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boards.
3041 Background: Profiling of targetable genetic alterations within molecular tumor boards (MTB) guides for personalized t...
Breast cancer–specific mortality in invasive lobular versus ductal carcinoma over 30 years.
636 Background: Invasive lobular carcinoma (ILC) differs biologically from invasive ductal carcinoma (IDC) and has been as...
Pathologic complete response in rare histologic subtypes of early-stage triple-negative breast cancer in the era of immunotherapy.
593 Background: The addition of immunotherapy (IO) to chemotherapy has improved outcomes in early-stage triple-negative br...
Apalutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): Final analysis from the retrospective real-world CAPABLE study.
e17103 Background: Apalutamide (APA) combined with androgen deprivation therapy (ADT) is the standard care for mHSPC and i...
Equity in breast cancer research authorship: Country, gender, and income representation in phase III trials presented at the ASCO Annual Meeting (2015–2025).
11083 Background: Equitable representation in global oncology research is essential for scientific validity, generalizabil...
Impact of immunotherapy infusion timing on overall and progression-free survival in advanced NSCLC.
e20573 Background: Circadian rhythms regulate immune function through central and peripheral molecular clocks, modulating...
IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC).
8086 Background: IMforte (NCT05091567) is the first positive phase 3 study of 1Lm in ES-SCLC to demonstrate statistically...
Incidence and risk: The epidemiology and long-term outcomes of early-onset luminal B breast cancer.
e12753 Background: Early-onset breast cancer is an increasing public health concern, with younger women disproportionately...
Analyzing variants and methylation in complex genomic regions using targeted long-read nanopore sequencing: A PKD case study.
e22644 Background: In oncology, actionable genomic and epigenomic alterations often occur in repetitive or other structura...
Prognostic impact of tumor suppressor and DNA damage repair gene mutations in oral cavity squamous cell carcinoma: A clinico-genomic analysis from a real-world database.
6065 Background: Oral cavity squamous cell carcinoma (OCSCC) has unique genomic features, yet molecular biomarkers predict...
Impact of <i>KRAS</i> sub-mutations in metastatic colorectal cancer patients (mCRC).
e15535 Background: KRAS mutations are established predictive and prognostic biomarkers in metastatic colorectal cancer (mC...
Real-world effectiveness of first-line niraparib maintenance therapy in Korean patients with advanced ovarian cancer: A multicenter retrospective cohort study.
e17562 Background: Although first-line maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors has signific...
Recurrence of ductal carcinoma in situ: A large South American multicenter analysis.
e12612 Background: Although ductal carcinoma in situ (DCIS) has minimal mortality, recurrence rates after surgery are clin...
Real-world outcomes associated with tarlatamab for extensive-stage small cell lung cancer (ES-SCLC) in the Veterans Health Administration (VA).
e20153 Background: ES-SCLC remains an aggressive malignancy with a very poor prognosis. Tarlatamab, a DLL3-targeted bispec...
Effectiveness and safety of IBI310 combined with sintilimab versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, controlled, multicenter phase III clinical study.
4148 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have demonstrated efficacy in aHCC. Despite impr...
Real-world treatment patterns and adherence to adjuvant abemaciclib among patients with early hormone receptor–positive (HR+) breast cancer (BC).
530 Background: Adjuvant abemaciclib (2 years) is approved in combination with endocrine therapy (ET) for node-positive hi...
Genomic characterization of brain metastasis in colorectal cancer to reveal patterns of clonal evolution and selection of driver mutations.
e15590 Background: Colorectal cancer (CRC) is a malignant tumor of the digestive system, known for its high incidence and...
Validation of a 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) for predicting survival in older adults with cancer.
1656 Background: The FI-CGA-10 is a content- and construct-validated measure for quantifying frailty from a CGA [Oncologis...
OnkoBank: A clinically annotated cancer biobank supporting translational and precision oncology research.
e15190 Background: High-quality, clinically annotated biobanks are essential infrastructure for translational cancer resea...
Performance of PREMMplus in a racially and ethnically heterogenous population undergoing germline multigene panel testing.
e22640 Background: PREMMplus is a risk prediction model that estimates the probability of carrying pathogenic germline var...
The importance of family history in indicating HBOC genetic testing in a resource-limited setting.
e12582 Background: Genetic screening for hereditary breast and ovarian cancer (HBOC) is guided by clinical criteria such a...
Baseline characteristics of NSCLC first-line immunotherapy super-responders in three European lung cancer centers: An ENDEAVOUR-IMIGO project.
8578 Background: Immune-checkpoint inhibitors (ICI) are part of first-line treatment concepts for most patients with metas...
Mitochondrial DNA (mtDNA) expression as used to define metabolic and immune states in colorectal cancer (CRC).
2647 Background: CRC exhibits metabolic reprogramming driven by the Warburg effect; however, active mitochondria and oxida...
Surgical resection versus stereotactic body radiation therapy in stage IV non–small cell lung cancer: A large, real-world, propensity-matched survival study.
8075 Background: The role of definitive local thoracic therapy in metastatic non–small cell lung cancer (NSCLC) remains co...
A mediation analysis of neurocognitive deficits and patient-reported mood among patients with lung cancer with brain metastases.
12044 Background: Advances in lung cancer therapeutics have led to a growing population of patients with lung cancer who a...